R87.810 is a valid billable ICD-10 diagnosis code for Cervical high risk human papillomavirus (HPV) DNA test positive . It is found in the 2020 version of the ICD-10 Clinical Modification (CM) and can be used in all HIPAA-covered transactions from Oct 01, 2019 - Sep 30, 2020 .
High risk human papillomavirus (HPV) DNA test positive from female genital organs 1 R87.81 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. 2 Short description: High risk HPV DNA test positive from female genital organs 3 The 2021 edition of ICD-10-CM R87.81 became effective on October 1, 2020. 4 This is the American ICD-10-CM version of R87.81 - other international versions of ICD-10 R87.81 may differ.
High risk human papillomavirus (HPV) DNA test positive from female genital organs. R87.81 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. Short description: High risk HPV DNA test positive from female genital organs.
It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as R87.81. A type 1 excludes note is for used for when two conditions cannot occur together , such as a congenital form versus an acquired form of the same condition.
There is a coding note indicating that the procedure code will identify the type of vaccine administered. For the virus, there is a screening code (Z11.51) that captures the screening for HPV.
Other primary sites of cancer origination include the back of the throat or tonsils. HPV is also the virus that causes genital warts. The CDC states that 80 percent of people will get an HPV infection in their lifetimes.
Vaginal cancer has no symptoms early, but patients can develop pelvic pain and vaginal discharge later. Vulvar cancer does have symptoms, which include color and skin changes, sores or lumps, itching, burning, and vulvar bleeding. It is important to note that not all vaginal/vulvar cancers are caused by HPV.
Local radio station personality goes public with his cancer fight. In August 2018, Marty Griffin, KDKA radio personality, announced to his listening audience that he had cancer. His cancer is related to human papilloma virus (HPV), which infects 80 million people, according to the Centers for Disease Control and Prevention (CDC).
This test can be ordered when a high-risk, HPV-positive test result has been obtained at a non−LabCorp test facility or as an add-on test if the positive high-risk HPV test was performed at LabCorp.
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
ThinPrep® vial 2 mL ( Note: This volume does not allow for repeat testing.)
Broom-like collection technique: Obtain a sample from the cervix using a broom-like device by inserting the brush portion into the cervical os and then rotate the brush five times.
Maintain specimen at room temperature. Specimens in ThinPrep® vials must be processed within 21 days of collection for HPV.
Patient should avoid douches 48 to 72 hours prior to examination. Specimen should not be collected during or shortly after menstrual period.
Improper collection; inadequate specimen; improper labeling; specimen leaked in transit; quantity not sufficient for analysis; name discrepancies; specimen submitted on male patient; specimen submitted in vial that expired according to manufacturer's label; frozen specimen; SurePath™ vial. For HPV: specimen more than 21 days old in ThinPrep® vial.